Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10147760 | 0.91 | NPC1 (0.45) | NPC1POLBPPM1BCHRNB2CHRNA5 | |
| SCHEMBL19393214 | 0.84 | NPC1 (0.51) | NPC1POLBPPM1BCHRNB2CHRNA5 | |
| SCHEMBL6974230 | 0.84 | NPC1 (0.51) | NPC1POLBPPM1BCHRNB2CHRNA5 | |
| SCHEMBL23895298 | 0.81 | NPC1 (0.46) | NPC1POLBPPM1B | |
| SCHEMBL10603926 | 0.81 | NPC1 (0.48) | NPC1POLBPPM1BCHRNB2CHRNA5 | |
| SCHEMBL10603914 | 0.81 | NPC1 (0.48) | NPC1POLBPPM1BCHRNB2CHRNA5 | |
| SCHEMBL20938370 | 0.81 | NPC1 (0.48) | NPC1POLBPPM1BCHRNB2CHRNA5 | |
| SCHEMBL9851830 | 0.81 | NPC1 (0.48) | NPC1POLBPPM1BCHRNB2CHRNA5 | |
| SCHEMBL4287430 | 0.79 | NPC1 (0.46) | NPC1POLBPPM1B | |
| SCHEMBL4288573 | 0.79 | NPC1 (0.46) | NPC1POLBPPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097718-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110275589-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-7560544-B2 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560544-B2 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275589-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | TLR5, THPO, IDO1 | NPC1 1441/4885POLB 3297/4885PPM1B 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.